2018年8月10日
及時發布，請聯系：
美國: (732) 993-9821
中國: +86-512-6745-1085 分機 101
info@amerigenpharma.com
根據《國務院關于修改〈建設項目竣工環境保護管理條例〉的決定》(國務院令第682號)，以及環保部《關于發布（建設項目竣工環境保護驗收暫行辦法）的公告》（國環規環評[2017]4號），現將蘇州愛美津制藥有限公司片劑生產擴建項目竣工情況公示如下：
項目名稱：蘇州愛美津制藥有限公司片劑生產擴建項目
建設單位：蘇州愛美津制藥有限公司
建設地址：蘇州工業園區群星一路58號
建設內容：公司擬投資1000萬元，在現有生產車間內擴建片劑生產項目，項目建成后具備年增產片劑3.8億片。
竣工時間：2018年8月10日。
調試日期：2018年8月11日-2018年8月12日。
公示期間，對上述公示內容如有異議，請以電話方式反饋。
聯系人：季健華
聯系方式：67451085-154
2018年8月10日
In accordance with the requirement of the State Council decision on amending “The Environmental Protection Regulations for the completion of construction projects” (Decree No. 682 of the State Council) and the announcement of the Ministry of Environmental Protection on the issue of “Interim Measures Of the Environmental Protection Acceptance For The Completion Of Construction Projects” (National Environmental Rules EIA [2017] No.4), the completion of the expansion project of Suzhou Amerigen Pharmaceutical Co., Ltd. is published as follows:
Project Name: Suzhou Amerigen Pharmaceutical Co., Ltd. Tablets Production Expansion
Construction Unit: Suzhou Amerigen Pharmaceutical Co., Ltd.
Construction Address: No.58, Qun Xing Yi Road, Suzhou Industrial Park
Construction Content: the company plans to invest 10 million RMB to expand the tablet production in the existing production workshop, and the production capacity will be increased of 380 million tablets per year after the project completion.
Completion Date: August 10, 2018
Commissioning Date: August 11, 2018 - August 12, 2018
If you have any objections during the publicity period, please contact Mr. Jianhua Ji via 67451085 (Ext. 154)
August 10, 2018
關于愛美津 About Amerigen
Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceutical Company Limited, is located in Suzhou, Jiangsu Province. The group has products on the market currently in both the US and China plus an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese CFDA. Amerigen's focus is orally delivered products that are potential first generics, challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.
愛美津制藥致力于仿制藥所涉及到的全部階段的業務，是一家包括美國和中國多成員企業的集團公司。集團由愛美津制藥控股。美國市場的注冊和商業活動由位于新澤西州，林赫斯特的美國愛美津負責；集團的中國分公司，蘇州愛美津制藥有限公司，位于中國江蘇省蘇州市。愛美津制藥集團目前在美國以及中國均有藥品上市和銷售，同時，我們擁有活躍的在研產品組，面向美國食品藥品監督管理局（FDA）注冊和已申報若干個仿制藥品種（ANDA），并且計劃開展向中國食品藥品監督管理局（CFDA）注冊和申報產品的工作。愛美津從事開發的口服制劑產品，是開發難度高，需要專門的技術，或生產要求高度嚴格管理控制，以及法規復雜，需要規避或挑戰專利的仿制藥。愛美津集團旗下公司或合作方開發和生產的所有產品，都滿足高質量標準，包括美國FDA。
